Read Simon
SEC Form 4 insider trading activity
Read Simon has filed 2 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, Read Simon is listed as Director at Dianthus Therapeutics, Inc. Inside the rolling window, Read Simon reported no open-market purchases and 2 open-market sales totaling $631K in DNTH. The largest disclosed transaction in the window is a sale of 2,778 DNTH shares on Aug 19, 2026, worth $327K.
Companies traded
Other insiders at DNTH
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$631K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Read Simon made?
Read Simon has filed 2 SEC Form 4 filings (9 transaction rows) across 1 company since 2026.
Which companies does Read Simon trade?
Read Simon has filed SEC Form 4 disclosures for 1 company, including DNTH.
When was Read Simon's most recent SEC Form 4 filing?
Read Simon's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is Read Simon's total buy and sell value in the current window?
Inside the rolling retention window, Read Simon bought $0 and sold $631K based on SEC Form 4 filings.
What was Read Simon's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,778 DNTH shares on 2026-08-19, worth $327K, per SEC Form 4 filings.